Clinical Trial Update: A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating tolvaptan to delay dialysis in infants and young children with autosomal recessive polycystic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Polycystic Kidney Disease

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Autosomal Recessive Polycystic Kidney Disease (ARPKD) | Phase 3 | Status: WITHDRAWN